



Missouri Pharmacy Program – Preferred Drug List



Thrombocytopenia Treatment Agents

Effective 04/04/2019

Preferred Agents for Chronic Immune Thrombocytopenia

- NPlate®
- Promacta®

Preferred Agents for short-term use in patients with chronic liver disease who are scheduled to undergo a procedure

- Mulpleta®

Non-Preferred Agents for Chronic Immune Thrombocytopenia

- Tavalisse™

Non-Preferred Agents for short-term use in patients with chronic liver disease who are scheduled to undergo a procedure

- Doptelet®

Approval Criteria

- For Chronic Immune Thrombocytopenia
 - Failure to achieve desired therapeutic outcomes with trial on 2 preferred agents
 - Appropriate age – 18 and older for Tavalisse and 1 year and older for Promacta and NPlate
 - Documented ADE/ADR to preferred agents
 - Documented trial of a corticosteroid
- For patients with chronic liver disease who are scheduled to undergo a procedure
 - Failure to achieve desired therapeutic outcomes with trial on 1 preferred agent
 - Documented ADE/ADR to preferred agent

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if no approval criteria are met
- Drug Prior Authorization Hotline: (800) 392-8030